Replimune Group (NASDAQ:REPL) Sets New 52-Week High – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL) shares reached a new 52-week high on Friday . The stock traded as high as $12.50 and last traded at $10.7980, with a volume of 9400383 shares traded. The stock had previously closed at $5.41.

Replimune Group News Roundup

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: FDA advisers voted 10-3 in favor of the clinical-trial data supporting RP1, overcoming concerns from FDA reviewers about the pivotal trial’s design and whether the results reliably demonstrated efficacy. FDA panel votes in favor of Replimune’s melanoma treatment
• Positive Sentiment: Replimune called the Cellular, Tissue, and Gene Therapies Advisory Committee outcome favorable as it seeks approval of its resubmitted Biologics License Application. The decision materially strengthens the regulatory outlook for RP1 and could support a future commercial launch in melanoma. Replimune announces favorable FDA committee outcome
• Positive Sentiment: Analysts described the panel result as “overwhelmingly positive,” with coverage pointing to higher perceived approval odds. The favorable vote triggered a major repricing of REPL shares after hours and in premarket trading. Analyst sees higher approval odds after panel outcome
• Neutral Sentiment: FDA advisers’ recommendation is influential but nonbinding; the agency will make the final approval decision. Investors should continue to monitor the FDA timeline, labeling terms, and any additional data requirements. Replimune surges after FDA advisers back skin cancer drug
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations related to Replimune, adding legal and reputational risk. The announcements provide no finding of wrongdoing and may have limited immediate impact compared with the FDA development. Pomerantz investor alert

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Jefferies Financial Group restated a “hold” rating and issued a $2.00 target price (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Cantor Fitzgerald cut Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $9.00 to $12.00 in a report on Friday. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. Finally, Leerink Partners restated a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.29.

Replimune Group Stock Performance

The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. The company’s 50-day moving average is $9.36 and its two-hundred day moving average is $7.36. The stock has a market capitalization of $916.85 million, a P/E ratio of -3.25 and a beta of 0.86.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, sell-side analysts anticipate that Replimune Group, Inc. will post -2.44 EPS for the current fiscal year.

Insider Activity

In related news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the transaction, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.20% of the company’s stock.

Institutional Trading of Replimune Group

Several hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after purchasing an additional 6,653 shares in the last quarter. Millennium Management LLC raised its stake in shares of Replimune Group by 2.8% during the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after purchasing an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after purchasing an additional 119,145 shares in the last quarter. Rhumbline Advisers lifted its holdings in Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after purchasing an additional 6,616 shares during the period. Finally, Sei Investments Co. lifted its holdings in Replimune Group by 149.5% in the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock worth $283,000 after purchasing an additional 18,263 shares during the period. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.